Apatinib Inhibits the Metabolic Clearance of Ropivacaine: An in vitro and in vivo Evaluation
Drug Design, Development and Therapy · 2026-08 · Volume 20 · 1-15
DOI: 10.2147/dddt.s608071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-08. Verfasst von Weiyi Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Wenzhou Vocational College of Science and Technology, Wenzhou City, Zhejiang, People's Republic of China. Hauptthemen laut MEDLINE: Ropivacaine, Pyridines, Anesthetics, Local. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Ropivacaine, a local anesthetic, is commonly used for surgical local anesthesia and labor analgesia.
Purpose
This study aimed to investigate the effect of apatinib on ropivacaine metabolism in vitro and in vivo, and to elucidate its inhibitory mechanism.
Methods
Following preliminary screening of 18 candidate drugs, apatinib was selected for further evaluation. An enzymatic reaction system was established using rat liver microsomes (RLM), human liver microsomes (HLM), and recombinant human CYP1A2 (rCYP1A2). The ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was developed for the simultaneous quantification of ropivacaine and its metabolite, 3-hydroxy ropivacaine.
Results
The UPLC-MS/MS method showed good linearity over 2– 250 ng/mL for ropivacaine and 1– 25 ng/mL for 3-hydroxy ropivacaine, respectively. Both showed intra- and inter-day precision (RSD%) below 15% and accuracy (RE%) within ± 15%. Apatinib inhibited ropivacaine metabolism in RLM, HLM, and rCYP1A2, with half-maximal inhibitory concentration (IC 50 ) values of 0.29, 9.12, and 2.49 μM, respectively. In the RLM metabolic stability assay, apatinib slowed ropivacaine metabolism and reduced its intrinsic clearance (CL int ) from 0.14 to 0.04 mL/min/mg. Enzyme kinetic analysis indicated non-competitive inhibition in all systems. In rats, co-administration with apatinib increased the area under the plasma concentration-time curve (AUC) and maximum plasma concentration (C max ) of ropivacaine by 0.83- and 0.71-fold, respectively, decreased the clearance (CL z/F ) by 47.17%.
Conclusion
Both in vitro and in vivo results indicated that apatinib inhibited the metabolism of ropivacaine. These findings provided essential reference data for the rational application of ropivacaine in clinical precision dosing regimens. Keywords: ropivacaine, drug-drug interaction, apatinib, metabolism, CYP1A2
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wenzhou Vocational College of Science and Technology, Wenzhou City, Zhejiang, People's Republic of China.
- Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
- Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang, People's Republic of China.
- The First School of Clinical Medicine, Wenzhou Medical University, Wenzhou City, Zhejiang, People's Republic of China.
ORCID-Profile: Jiaojiao Dong, Fangfang Xia
Zitieren
APA
Zhang, W., Wang, P., Cai, Y., Feng, C., Dong, J., Jin, Z., & Xia, F. (2026). Apatinib Inhibits the Metabolic Clearance of Ropivacaine: An in vitro and in vivo Evaluation. Drug Design, Development and Therapy, Volume 20, 1-15. https://doi.org/10.2147/dddt.s608071
Vancouver
Zhang W, Wang P, Cai Y, Feng C, Dong J, Jin Z, et al. Apatinib Inhibits the Metabolic Clearance of Ropivacaine: An in vitro and in vivo Evaluation. Drug Design, Development and Therapy. 2026;Volume 20:1-15. doi:10.2147/dddt.s608071
BibTeX
@article{Zhang2026,
author = {Zhang, Weiyi and Wang, Peiqi and Cai, Yaoyao and Feng, Chengyao and Dong, Jiaojiao and Jin, Zhousheng and Xia, Fangfang},
title = {Apatinib Inhibits the Metabolic Clearance of Ropivacaine: An in vitro and in vivo Evaluation},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--15},
doi = {10.2147/dddt.s608071}
}
EUVIMED